Dr. Danny Ray Westmoreland, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 16 2nd St, Mason, WV 25260 Phone: 304-773-5333 Fax: 304-773-5885 |
News Archive
The ALS Therapy Development Institute announced today that it is supporting a new awareness campaign driven by several ALS patients diagnosed with the progressive neurodegenerative disease commonly known as Lou Gehrig's disease before the age of 30. This campaign, called "Young Faces of ALS," is designed and led by a group of seven young men and women and will consist of a group effort to visit each of the 30 Major League Baseball parks during the 2010 baseball season.
In this CNN opinion piece, Julian Zelizer, an author and professor of history and public affairs at Princeton University, reports on how, "as the super-committee deliberates over how to reduce the deficit and other congressional committees struggle to cut spending, the fate of important programs," such as PEPFAR, "hangs in the balance."
Many research groups have and are investigating main protease inhibitors as antiviral drugs, and in a paper recently uploaded to the bioRxiv* preprint server, a team of researchers examine the crystal structure of the protein while bound to various viral substrate peptides (P1-4). In doing so, they reveal the way in which the bound peptide sequence can direct and modulate enzyme activity, providing new templates towards antiviral drug design.
Upsher-Smith Laboratories, Inc. presented data from a 52-week, open-label extension study (PREVAIL OLE) showing that Qudexy XR (topiramate) extended-release capsules offered a long-term adjunctive treatment option with a favorable tolerability profile for a high proportion of patients with refractory partial-onset seizures (POS).
› Verified 3 days ago